The two big and expensive new cholesterol drugs that everyone is talking about have both been added to the national preferred formulary of Express Scripts, the nation’s largest pharmacy benefit manager. The drugs– alirocumab (Praluent, from Regeneron and Sanofi) and evolocumab (Repatha, from Amgen)– are potent but expensive drugs that inhibit PCSK9 and dramatically lower LDL cholesterol. Both drugs…
New Cholesterol Drugs Not Breaking The Bank– Yet
October 1, 2015 by Leave a Comment
Sales of the new cholesterol-lowering PCSK9 inhibitors have been lower than some had anticipated, the nation’s largest pharmacy benefit manager, Express Scripts, disclosed in a Reuters news story. The majority of prescriptions have been rejected by Express Scripts “because patients did not meet required medical criteria,” Reuters reported. “We’re seeing a lot of patients who either don’t qualify or…
Recent Comments